Business
Piper Jaffray GenomeRx Symposium in New York
Piper Jaffray GenomeRx Symposium in New York.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 1869K Oxford Biomedica PLC 20 June 2014 \n \n\n \n \n \n \n \n \nOxford BioMedica to participate at the Piper Jaffray GenomeRx Symposium in New York on 23 June 2014\n \n \nOxford, UK - 20 June 2014: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray's GenomeRx Symposium on Monday, June 23, 2014 at The Yale Club, New York.\nOxford BioMedica's Chief Executive Officer, John Dawson, and Kyriacos Mitrophanous PhD, Head of Research, will take part in a panel discussion entitled \"Ophthalmology: Seeing The Future of Gene Therapy Clearly\" detailing trends for gene therapy in ophthalmology from 12:45 - 1:40 pm (UTC).\n \n- Ends -\n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nMedia Enquiries:\nMary-Jane Elliott/Emma Thompson/Matthew Neal\nConsilium Strategic Communications\n\n\n \n \nTel: +44 (0)20 3709 5700\n\n\n\n\n \nNote to editors\n \nAbout Oxford BioMedica®\nOxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.\n \n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NRALLFVVRRIIFIS\n ","length":4098,"tagName":"div"}]